Civica Rx

Civica Rx - "the nonprofit model for manufacturing." This piece, from The Medicine Maker magazine, shares highlights of our progress, our partners and our new sterile injectable manufacturing facility in City of Petersburg, VA. Excerpts: "All companies claim to put patients first, but how true is that really when the corporate pharma business revolves around profits? Civica Rx is approaching generic drug manufacturing using a nonprofit model – and it’s working... "Civica is supplying nearly 80 different generic medicines to member hospitals – and has provided over 185 million doses to date. It has also opened its own manufacturing facility in Petersburg, Virginia, with the capacity to produce 90 million vials and 50 million pre-filled syringes of medicines every year... "According to Civica's Jason Winfield, site director of engineering and technical services, there has been a big focus for some time on bringing production closer to home. 'A lot of pharmaceutical manufacturing takes place in India and China, but there have been widely publicized issues with sterile injectables. And although India is a great provider of APIs, they get a lot of their precursors from China. During the COVID-19 pandemic, materials stopped moving – and this hasn’t ended with COVID; there are still ongoing challenges in supply chains.'” Excerpts from equipment partners: From Matt Clifton, business development manager at groninger USA: "From the very start of Civica, the company was unique. A lot of people in the industry were watching them closely. They had smart people on the business side and significant industry leadership with a ton of manufacturing experience. However, I think there was some doubt early on about whether they could pull it off and if there would be any compromises on quality. But they’ve done it – their products are excellent and their facility is one of the best facilities I’ve visited. They use high-end solutions and they understand what they are doing. They are top tier in the industry.” From SKAN's Marc Suter: “It’s hard not to feel personally moved when you hear the story behind Civica. Somebody needs to tackle drug shortages, but it may not be profitable to do so for some companies. The result is that patients have to go without their medicines. I’m proud to be part of a project that is trying to change that. Civica isn’t just focused on generic drugs; they also have plans to make affordable insulin. I really wasn’t aware of how difficult the situation is in the US compared with Europe, where I am based. If you follow through and stand with something, you can make changes in this industry. It’s been amazing to watch what Civica has done.” Thanks to the teams at groninger & co. gmbh and SKAN for helping to bring our new manufacturing facility to life! https://lnkd.in/eCB2ebgQ

Civica Rx has been nominated as a BioSpace Best Place to Work! Voting is open through this month and anyone can participate by voting on two biopharma industry categories, large company and small company (Civica is listed as a candidate in the small company section). Participants vote on their top three large and small companies from a predetermined list (with a few more questions for the #1 pick in each category). The survey takes about 5 minutes and no comments/essays are required. Civica was named a 2024 BioSpace Best Place to Work and we are proud to be nominated again! https://lnkd.in/gk457-Bt

Way to represent, Aneitra Viney, and thank you for helping to make essential, quality generic medications available and affordable to all! Brightpoint Community College’s new pharmaceutical manufacturing career studies certificate (CSC) helps prepare professionals for working in our exciting industry. Civica Rx is a Brightpoint partner and is already benefiting from the participation of Brightpoint classmates at our Civica Petersburg facility. In this feature below, Aneitra shares comments on the Brightpoint program and on joining Civica. Congrats to all!

#ICYMI Exciting progress in the pharmaceutical Industry, as shared by Healthcare Packaging author Keren Sookne. At non-profit Civica Rx, innovation isn't just about cost-saving measures—it's about investing in cutting-edge technology to make healthcare affordable and available for all. Instead of opting for entry-level equipment, Civica Rx prioritized high-quality, high efficiency filling systems from the start. In just five years since their launch, Civica Rx has made significant strides. From securing contracts with established manufacturing sites to now producing their own engineering batches in their state-of-the-art injectable drug facility in Petersburg, VA, their progress is nothing short of remarkable. Healthcare packaging captures their thought process, their need for flexibility, and why they selected an isolator-integrated vial filling line and nest filling line from groninger Group and SKAN. Thank you Jason Winfield Matt Clifton and Marc Suter for sharing your insights for this story! Learn more: https://lnkd.in/e3wUAsR6 #pharmapackaging #injectables #affordabledrugs #pharmaceuticals #fillingtechnology #isolator

Sending thanks and congratulations to the Commonwealth of Virginia! “We enthusiastically congratulate Virginia for this well-deserved recognition,” said Ned McCoy, President and CEO of Civica Rx. “We know first-hand of the Commonwealth’s dedication and expertise in growing businesses that are essential to the community and our country... "Most recently, the Virginia Economic Development Partnership's Talent Accelerator Team has helped us create innovative training programs for Civica’s new hires, leaders and growing teams at our new manufacturing facility in Petersburg, our future home of affordable insulin and essential medicines hospitals use every day.” https://lnkd.in/eRkSUsFi

We applaud U.S. Sen. Jacky Rosen's efforts to launch a U.S. Department of Health and Human Services (HHS) inquiry into PBMs that are blocking patient access to low-cost generic medicines. PBMs that profit from higher-priced medicines have a financial disincentive to provide access to low-cost generics, such as those offered by CivicaScript. Profit should not come before patients. https://lnkd.in/ezqVfqRi

Wow! We just learned that Virginia has again been ranked as number one in the U.S. for customized workforce training. We know first-hand of the dedication and expertise of the Virginia Economic Development Partnership's Talent Accelerator Team. They have helped create and implement innovative training programs for Civica Rx's new hires, leaders and growing teams at our new manufacturing facility in the City of Petersburg, VA. Our state-of-the-art Commonwealth of Virginia facility is the future home of affordable insulin and essential medicines hospitals use every day. “The breadth and speed with which this VEDP program begins to deliver for companies is a highlight that Business Facilities magazine is pleased to recognize in this year’s ranking,” said Business Facilities Editorial Director Anne Cosgrove. “The capability to provide training for businesses across a variety of industries to meet their specific needs is a feature that stands out with the Virginia Talent Accelerator Program.” We send heartfelt congratulations to VEDP and the Talent Accelerator Program on this outstanding accomplishment. Thank you for all you do in support of our mission to ensure quality generic medications are available and affordable to everyone! https://lnkd.in/d9AAWi7w

$3 Million in savings for one medication with CivicaScript and Highmark Inc. We're proud to be driving these savings for consumers through our low-cost medication to help treat prostate cancer. This is what inspires us as we work to make quality generic medicines affordable and available to everyone. https://lnkd.in/dbvNMpYc

This new drug shortage report is alarming but not surprising. It shows that the average shortage is lasting three years and getting longer. It demonstrates how price is predictive of a shortage. And, it reports that new shortages in 2023 were predominantly associated with the US and EU. From US Pharmacopeia: "The insights in the USP Annual Drug Shortages Report are derived from USP’s Medicine Supply Map. It uses artificial intelligence and predictive analytics to identify, characterize, and predict risk in the complex supply chain for manufacturing drug products and their ingredients... "The report provides an in-depth analysis of the factors leading to increased shortages in 2023, particularly in generic sterile injectable medicines. With the average duration of shortages exceeding three years, it's more important than ever to equip your organization to anticipate and mitigate these risks." Key report highlights: --Economic factors: The impact of pricing and manufacturing complexities on drug shortages. --Geographic concentration: How the centralization of production can increase vulnerability. --Quality concerns: Highlighting quality issues from regulatory inspections and recalls that can indicate drug shortage risks. Civica Rx is becoming a part of the solution, ensuring a reliable supply of quality medications for approximately 1,500 member hospitals across the U.S. through longer-term contracts (providing predictability for both hospitals and the manufacturer), fair and sustainable pricing, buffer inventory and a relentless focus on quality. We are also boosting U.S. based sterile injectable manufacturing capability through our new, state-of-the-art facility in City of Petersburg, VA, outside of Richmond, VA. https://lnkd.in/e5ipNB5A